IQVIA (IQV) vs MaxCyte (MXCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
IQVIA (IQV) has outperformed MaxCyte (MXCT) over the past year, gaining 28.5% versus a loss of 32.9%. Over five years, IQV leads with a +3.7% price change compared with -90.6% for MXCT. IQVIA is the larger company by market cap ($42.62 billion vs $105.3 million), about 404.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IQV | MXCT |
|---|---|---|
| Share price | $258.91 | $1.02 |
| Market cap | $42.62B | $105.27M |
| 1-day change | +0.31% | -1.92% |
| YTD return | +14.51% | -32.90% |
| 1-year return | +28.50% | -32.90% |
| 5-year return | +3.72% | -90.57% |
| P/E ratio (TTM) | 32.16 | — |
| Forward P/E | 17.95 | — |
| EPS (TTM) | $8.05 | $-0.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $16.31B | — |
| Revenue growth (YoY) | +5.87% | — |
| Net income (latest FY) | $1.36B | — |
| Gross margin | 33.29% | — |
| Operating margin | 13.38% | — |
| Net margin | 8.34% | — |
| 52-week high | $277.40 | $1.87 |
| 52-week low | $154.50 | $0.643 |
| Distance from 52-week high | -6.67% | -45.31% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +12.33% | — |
| Average volume | 1.45M | 685.34K |
| Shares outstanding | 164.60M | 103.21M |
| Employees | 94,000 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IQVIA is about 404.8 times larger than MaxCyte by market value ($42.62B vs $105.27M).
- IQV has outperformed MXCT by 61.4 percentage points over the past year.
About IQVIA
IQV stock →IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 94,000 employees
IQV vs MXCT FAQ
Which is bigger, IQVIA or MaxCyte?
IQVIA (IQV) is larger, with a market capitalization of $42.62B compared with $105.27M for MaxCyte (MXCT).
Which stock has performed better over the past year, IQV or MXCT?
IQV returned +28.50% over the past 12 months, compared with -32.90% for MXCT (price return, excluding dividends). Past performance does not predict future results.
Are IQVIA and MaxCyte in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.